| Status: Recommended | ||
Adalimumab (Humira®) is recommended as an option for use within NHS Wales for the treatment of moderately to severely active ulcerative colitis in paediatric patients (from 6 years of age) who have had an inadequate response to conventional therapy including corticosteroids and/or 6- mercaptopurine (6-MP) or azathioprine (AZA), or who are intolerant to or have medical contraindications for such therapies. |
||
|
||
Medicine details |
||
| Medicine name | adalimumab (Humira®) | |
| Formulation | 40 mg/0.4 ml and 80 mg/0.8 ml solution for injection in pre-filled pen or syringe | |
| Reference number | 4526 | |
| Indication | Treatment of moderately to severely active ulcerative colitis in paediatric patients (from 6 years of age) who have had an inadequate response to conventional therapy including corticosteroids and/or 6-mercaptopurine (6-MP) or azathioprine (AZA), or who are intolerant to or have medical contraindications for such therapies |
|
| Company | AbbVie Ltd | |
| BNF chapter | Gastro-intestinal system | |
| Submission type | Licence extension for paediatric use | |
| Status | Recommended | |
| Advice number | 0622 | |
| AWMSG meeting date | 08/03/2022 | |
| Date of issue | 16/03/2022 | |
| Further information Recommended in adults by NICE TA329: Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy |
||